ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares
On January 8, 2024, CEO Stephen Davis sold 3,732 shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) according to a recent SEC Filing. Following this transaction, the insider's total sales over the past year amount to 247,136 shares, with no recorded purchases in the same period.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
The insider transaction history for ACADIA Pharmaceuticals Inc shows a pattern of insider selling, with 34 insider sells and only 1 insider buy over the past year.
On the valuation front, ACADIA Pharmaceuticals Inc's shares were trading at $29.96 on the day of the insider's recent transaction. The company's market cap stands at $4.716 billion.
The stock's price-to-GF-Value ratio is 1.03, indicating that it is Fairly Valued in relation to its GF Value of $29.13. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is derived from historical trading multiples, an adjustment factor based on the company's historical performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
